Cardiovascular outcomes after hematopoietic stem cell transplantation
Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation (CORE-HCT): A Prospective Multicenter Observational Study
Peking University People's Hospital · NCT07349498
We will collect clinical, laboratory, and treatment data from people who had hematopoietic stem cell transplants to see if certain factors are linked to heart and blood vessel problems after transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Sex | All |
| Sponsor | Peking University People's Hospital (other) |
| Locations | 16 sites (Beijing, Beijing Municipality and 15 other locations) |
| Trial ID | NCT07349498 on ClinicalTrials.gov |
What this trial studies
This is a prospective, multicenter observational cohort of patients who received hematopoietic cell transplantation at participating centers. Investigators will enroll transplant recipients and collect clinical characteristics, laboratory profiles, management measures, and follow-up data on cardiovascular events. Data will be gathered prospectively across several major tertiary hospitals and pooled for analysis of incidence and risk factors. The aim is to characterize post-transplant cardiovascular outcomes and drivers of risk to inform future care strategies.
Who should consider this trial
Good fit: Patients who undergo hematopoietic cell transplantation at any participating center and agree to prospective data collection are eligible to join.
Not a fit: People who did not receive a transplant at a participating site, who withdraw consent, or whose other medical conditions make data interpretation unreliable are unlikely to gain direct benefit from this project.
Why it matters
Potential benefit: If successful, the findings could help identify patients at higher risk of cardiovascular complications after transplant so clinicians can tailor monitoring and prevention.
How similar studies have performed: Previous observational cohorts have documented increased cardiovascular risk after hematopoietic cell transplantation and identified some risk factors, but large prospective multicenter efforts to refine risk prediction have been limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who undergo hematopoietic cell transplantation at any of the participating medical centers. Exclusion Criteria: * Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data. * Patient request to withdraw from the study.
Where this trial is running
Beijing, Beijing Municipality and 15 other locations
- Chinese PLA General Hospital — Beijing, Beijing Municipality, China (RECRUITING)
- Peking University First Hospital — Beijing, Beijing Municipality, China (RECRUITING)
- Peking University People's Hospital — Beijing, Beijing Municipality, China (RECRUITING)
- Peking University Third Hospital — Beijing, Beijing Municipality, China (RECRUITING)
- Xinqiao hospital of the third military medical university — Chongqing, Chongqing Municipality, China (RECRUITING)
- Sun Yat-sen University Cancer Center, Sun Yat-sen University — Guangzhou, Guangdong, China (RECRUITING)
- Peking University Shenzhen Hospital — Shenzhen, Guangdong, China (RECRUITING)
- First Affiliated Hospital of Harbin Medical University — Harbin, Heilongjiang, China (RECRUITING)
- The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (RECRUITING)
- Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology — Wuhan, Hubei, China (RECRUITING)
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (RECRUITING)
- First Affiliated Hospital Xi'an Jiaotong University — Xi'an, Shaanxi, China (RECRUITING)
- Sichuan Provincial People's Hospital — Chengdu, Sichuan, China (RECRUITING)
- Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences) — Tianjin, Tianjin Municipality, China (RECRUITING)
- First Affiliated Hospital of Xinjiang Medical University — Ürümqi, Xinjiang, China (RECRUITING)
- First Affiliated Hospital of Zhejiang University — Hangzhou, Zhejiang, China (RECRUITING)
Study contacts
- Study coordinator: Xiao Hui Zhang
- Email: zhangxh@bjmu.edu.cn
- Phone: 861088324577
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hematopoietic Stem Cell Transplantation, Transplant Complication, Cardiovascular Events